| Drug Type Fc fusion protein | 
| Synonyms INES 103, INES-103, INES103 | 
| Target- | 
| Action stimulants | 
| Mechanism ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), T lymphocytes stimulants | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhaseIND Approval | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Hematologic Neoplasms | IND Approval | China  | 05 Jan 2023 | |
| Solid tumor | IND Approval | United States  | 22 Dec 2022 | |
| Solid tumor | IND Approval | United States  | 22 Dec 2022 | 






